These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp). Xie Z; Feng S; Wang Y; Cao C; Huang J; Chen Y; Kong Y; Li Z Eur J Med Chem; 2015 Sep; 102():363-74. PubMed ID: 26298494 [TBL] [Abstract][Full Text] [Related]
26. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Natarajan A; Zaman AG; Marshall SM Diab Vasc Dis Res; 2008 Jun; 5(2):138-44. PubMed ID: 18537103 [TBL] [Abstract][Full Text] [Related]
27. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy. Lippi G; Montagnana M; Danese E; Favaloro EJ; Franchini M Biomark Med; 2011 Feb; 5(1):63-70. PubMed ID: 21319966 [TBL] [Abstract][Full Text] [Related]
28. Recent therapeutic approaches to platelet activation in coronary artery disease. Tousoulis D; Paroutoglou IP; Papageorgiou N; Charakida M; Stefanadis C Pharmacol Ther; 2010 Aug; 127(2):108-20. PubMed ID: 20546778 [TBL] [Abstract][Full Text] [Related]
29. Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy. Tautz L; Senis YA; Oury C; Rahmouni S Bioorg Med Chem; 2015 Jun; 23(12):2786-97. PubMed ID: 25921264 [TBL] [Abstract][Full Text] [Related]
30. Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb-IIIa. Frojmovic MM; Kasirer-Friede A; Goldsmith HL; Brown EA Thromb Haemost; 1997 Mar; 77(3):568-76. PubMed ID: 9066012 [TBL] [Abstract][Full Text] [Related]
31. Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems. Horiuchi H Ann Med; 2006; 38(3):162-72. PubMed ID: 16720431 [TBL] [Abstract][Full Text] [Related]
32. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets. Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439 [TBL] [Abstract][Full Text] [Related]
33. The antiplatelet effects of a new nitroderivative of acetylsalicylic acid--an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production. Lechi C; Andrioli G; Gaino S; Tommasoli R; Zuliani V; Ortolani R; Degan M; Benoni G; Bellavite P; Lechi A; Minuz P Thromb Haemost; 1996 Nov; 76(5):791-8. PubMed ID: 8950792 [TBL] [Abstract][Full Text] [Related]
34. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy. Rozalski M; Nocun M; Watala C Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207 [TBL] [Abstract][Full Text] [Related]
35. Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis. Momi S; Caracchini R; Falcinelli E; Evangelista S; Gresele P Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):820-9. PubMed ID: 24558107 [TBL] [Abstract][Full Text] [Related]
37. Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. Angiolillo DJ; Ferreiro JL Am J Cardiovasc Drugs; 2013 Aug; 13(4):233-50. PubMed ID: 23613159 [TBL] [Abstract][Full Text] [Related]
38. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents. Madsen NJ; Holmes CE; Serrano FA; Sobel BE; Schneider DJ Am J Cardiol; 2007 Aug; 100(4):722-7. PubMed ID: 17697836 [TBL] [Abstract][Full Text] [Related]